 | Up a level |
Journal Article
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D., Kreuzer, K. -A., Godley, L., Collins, R., Atallah, E., Azarnia, N. and Silverman, L. (2015). OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED, CONTROLLED, PHASE III STUDY OF RIGOSERTIB. Haematologica, 100. S. 238 - 239. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Azarnia, N., Petrone, M. E., Snyder, B. R., Maniar, M. and Silverman, L. R. (2015). RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). Leuk. Res., 39. S. S57 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Azarnia, N., Petrone, M. E., Snyder, B. R., Maniar, M. and Silverman, L. R. (2015). RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). Leuk. Res., 39. S. S57 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835
Silverman, L., Fenaux, P., Al-Kali, A., Baer, M., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D., Kreuzer, K. -A., Godley, L., Collins, R., Atallah, E., Azarnia, N. and Garcia-Manero, G. (2015). PROGNOSTIC AND PREDICTIVE VALUE OF IPSS-R IN ASSESSING OVERALL SURVIVAL (OS) IN A PHASE III STUDY OF RIGOSERTIB IN SECOND-LINE HIGHER-RISK (HR) MDS PATIENTS. Haematologica, 100. S. 492 - 493. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Navada, S. C., Azarnia, N. and Garcia-Manero, G. (2015). BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION? Leuk. Res., 39. S. S44 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835
Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Navada, S. C., Azarnia, N. and Garcia-Manero, G. (2015). BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION? Leuk. Res., 39. S. S44 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835